Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover

Trial Profile

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Raynaud's disease; Scleroderma; Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms STAR
  • Sponsors Cytori Therapeutics
  • Most Recent Events

    • 24 Jul 2017 Top-line 24- and 48-week results published in a Cytori Therapeutics media release.
    • 24 Jul 2017 Primary endpoint (Cochin score) has not been met, according to a Cytori Therapeutics media release.
    • 10 Jul 2017 According to a Cytori Therapeutics media release, Dinesh Khanna, M.D., M.S., the Frederick G.L. Huetwell Professor of Rheumatology, Professor of Internal Medicine, and Director of the Scleroderma Program at the University of Michigan is one of the principal investigators of the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top